Literature DB >> 27380015

Correction: Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials.

.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0153740.].

Entities:  

Year:  2016        PMID: 27380015      PMCID: PMC4933346          DOI: 10.1371/journal.pone.0158928

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Fig 1 is incorrect. Please see the correct Fig 1 here. The publisher apologizes for the error.
Fig 1

PRISMA flow diagram according to [50] summarising study selection for clinical trials reporting safety (left) and efficacy (right) outcomes, respectively.

Search terms employed were: methotrexate [Title] AND (psoriasis [Title] OR arthritis [Title] OR Crohn’s [Title] OR ulcerative colitis [Title] OR ankylosing spondylitis [Title]) AND (trial [Title] OR Study [Title]) for safety studies and: Search: methotrexate [Title] AND psoriasis [Title] AND (trial [Title] OR Study [Title]) for efficacy studies.

PRISMA flow diagram according to [50] summarising study selection for clinical trials reporting safety (left) and efficacy (right) outcomes, respectively.

Search terms employed were: methotrexate [Title] AND (psoriasis [Title] OR arthritis [Title] OR Crohn’s [Title] OR ulcerative colitis [Title] OR ankylosing spondylitis [Title]) AND (trial [Title] OR Study [Title]) for safety studies and: Search: methotrexate [Title] AND psoriasis [Title] AND (trial [Title] OR Study [Title]) for efficacy studies.
  1 in total

1.  Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials.

Authors:  Jonathan West; Simon Ogston; John Foerster
Journal:  PLoS One       Date:  2016-05-11       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.